Dr. Monika Balzer-Geldsetzer

Seit 2006

Studienkoordinatorin und Projektmanagerin in der Arbeitsgruppe Versorgungsforschung (AG Dodel) in der Klinik für Neurologie, Philipps-Universität Marburg

2002-2006

Post-Doc In der Chirurgie des Klinikums Rechts der Isar, München

1998 - 2002

Post-Doc im Institut für Pharmakologie & Toxikologie der Karl-Franzens-Universität Graz, Österreich; davon zwei Jahre als Individualstipendiatin der EU (Marie-Curie-Grant)

1998

Promotion im Institut für Physikalische Biologie (AG R. Wagner) an der Heinrich-Heine-Universität Düsseldorf

1994                                            

Diplom-Studium der Biologie an der Heinrich-Heine-Universität Düsseldorf (Schwerpunkt Parasitologie)

1. Originalarbeiten

Prescription of Benzodiazepines and Related Drugs in Patients with Mild Cognitive Deficits and Alzheimer's Disease. Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M. Pharmacopsychiatry. 2018 Jan 31.

Antidepressant medication in a German cohort of patients with Alzheimer's disease. Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M. Int J Clin Pharmacol Ther. 2018 Mar;56(3): 101-112.

Antipsychotic treatment of community-dwelling and institutionalised patients with dementia in Germany. Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M. Int J Psychiatry Clin Pract. 2017 Dec 13:1-8.

Use of antidementia drugs in German patients with Alzheimer's disease. Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M. Int Clin Psychopharmacol. 2017 Nov 6

Predictors of noninstitutionalized survival 1 year after hip fracture: A prospective observational study to develop the Marburg Rehabilitation Tool for Hip fractures (MaRTHi). Buecking B, Eschbach D, Knobe M, Oberkircher L, Balzer-Geldsetzer M, Dodel R, Sielski R, Doering B, Ruchholtz S, Bliemel C. Medicine (Baltimore). 2017 Sep; 96(37):e7820.

Prevalence, Duration and Severity of Parkinson's Disease in Germany: A Combined Meta-Analysis from Literature Data and Outpatient Samples. Enders D, Balzer-Geldsetzer M, Riedel O, Dodel R, Wittchen HU, Sensken SC, Wolff B, Reese JP. Eur Neurol. 2017;78(3-4):128-136.

[Differences Between Self- and Proxy-Assessment of Health-Related Quality of Life in Patients with Mild Cognitive Impairment and Alzheimer's Disease]. Heßmann P, Dreier M, Brandes I, Dodel R, Baum E, Müller MJ, Balzer-Geldsetzer M. Psychiatr Prax. 2017 Feb 27. doi: 10.1055/s-0042-121169 . [Epub ahead of print] German.

Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia. Kronimus Y, Albus A, Balzer-Geldsetzer M, Straub S, Semler E, Otto M, Klotsche J, Dodel R; LANDSCAPE Consortium, Mengel D. PLoS One. 2016 Nov 1;11(11):e0164953.

Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study. Kalbe E, Rehberg SP, Heber I, Kronenbuerger M, Schulz JB, Storch A, Linse K, Schneider C, Gräber S, Liepelt-Scarfone I, Berg D, Dams J, Balzer-Geldsetzer M, Hilker R, Oberschmidt C, Witt K, Schmidt N, Mollenhauer B, Trenkwalder C, Spottke A, Roeske S, Wittchen HU, Riedel O, Dodel R. J Neurol Neurosurg Psychiatry. 2016 Oct; 87(10):1099-105.

Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease. Mengel D, Dams J, Ziemek J, Becker J, Balzer-Geldsetzer M, Hilker R, Baudrexel S, Kalbe E, Schmidt N, Witt K, Liepelt-Scarfone I, Gräber S, Petrelli A, Neuser P, Schulte C, Linse K, Storch A, Wittchen HU, Riedel O, Mollenhauer B, Ebentheuer J, Trenkwalder C, Klockgether T, Spottke A, Wüllner U, Schulz JB, Reetz K, Heber IA, Ramirez A, Dodel R. Parkinsonism Relat Disord. 2016 Aug;29: 112-6.

Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications. Dams J, Balzer-Geldsetzer M, Siebert U, Deuschl G, Schuepbach WM, Krack P, Timmermann L, Schnitzler A, Reese JP, Dodel R; EARLYSTIM-investigators. Mov Disord. 2016 Aug;31(8): 1183-91.

Verbal memory declines more in female patients with Parkinson's disease: the importance of gender-corrected normative data. Fengler S, Roeske S, Heber I, Reetz K, Schulz JB, Riedel O, Wittchen HU, Storch A, Linse K, Baudrexel S, Hilker R, Mollenhauer B, Witt K, Schmidt N, Balzer-Geldsetzer M, Dams J, Dodel R, Gräber S, Pilotto A, Petrelli A, Fünkele S, Kassubek J, Kalbe E. Psychol Med. 2016 Aug;46(11):2275-86.

Pre-fracture quality of life predicts 1-year survival in elderly patients with hip fracture-development of a new scoring system. Bliemel C, Sielski R, Doering B, Dodel R, Balzer-Geldsetzer M, Ruchholtz S, Buecking B. Osteoporos Int. 2016 Jun;27(6):1979-87.

TREM2 rare variant p.R47H is not associated with Parkinson's disease. Mengel D, Thelen M, Balzer-Geldsetzer M, Söling C, Bach JP, Schaeffer E, Herold C, Becker T, Liepelt I, Becker J, Riedel-Heller S, Scherer M, Jessen F, Maier W, Dodel R, Ramirez A. Parkinsonism Relat Disord. 2016 Feb; 23:109-11.

Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings. Heßmann P, Seeberg G, Reese JP, Dams J, Baum E, Müller MJ, Dodel R, Balzer-Geldsetzer M. J Alzheimers Dis. 2016;51(2):545-61.

Impact of Parkinson's disease on the acute care treatment and medium-term functional outcome in geriatric hip fracture patients. Bliemel C, Oberkircher L, Eschbach DA, Lechler P, Balzer-Geldsetzer M, Ruchholtz S, Buecking B. Arch Orthop Trauma Surg. 2015 Nov;135(11):1519-26.

Factors influencing the progress of mobilization in hip fracture patients during the early postsurgical period?-A prospective observational study. Buecking B, Bohl K, Eschbach D, Bliemel C, Aigner R, Balzer-Geldsetzer M, Dodel R, Ruchholtz S, Debus F. Arch Gerontol Geriatr. 2015 May-Jun;60(3):457-63.

Effect of Preexisting Cognitive Impairment on In-Patient Treatment and Discharge Management among Elderly Patients with Hip Fractures. Bliemel C, Lechler P, Oberkircher L, Colcuc C, Balzer-Geldsetzer M, Dodel R, Ruchholtz S, Buecking B. Dement Geriatr Cogn Disord. 2015;40(1-2):33-43.

What determines health-related quality of life in hip fracture patients at the end of acute care?--a prospective observational study. Buecking B, Struewer J, Waldermann A, Horstmann K, Schubert N, Balzer-Geldsetzer M, Dodel R, Bohl K, Ruchholtz S, Bliemel C. Osteoporos Int. 2014 Feb;25(2):475-84.

Re-admission to Level 2 unit after hip-fracture surgery - Risk factors, reasons and outcome. Buecking B, Eschbach D, Koutras C, Kratz T, Balzer-Geldsetzer M, Dodel R, Ruchholtz S. Injury. 2013 Dec;44(12):1919-25.

Preference-based Health status in a German outpatient cohort with multiple sclerosis. Reese JP, Wienemann G, John A, Linnemann A, Balzer-Geldsetzer M, Mueller UO, Eienbröker C, Tackenberg B, Dodel R. Health Qual Life Outcomes. 2013 Oct 3;11:162.

The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice. Stuckenholz V, Bacher M, Balzer-Geldsetzer M, Alvarez-Fischer D, Oertel WH, Dodel RC, Noelker C. J Parkinsons Dis. 2013;3(2):161-72.

Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease. Dams J, Klotsche J, Bornschein B, Reese JP, Balzer-Geldsetzer M, Winter Y, Schrag A, Siderowf A, Oertel WH, Deuschl G, Siebert U, Dodel R. Health Qual Life Outcomes. 2013 Mar 8;11:35.

Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany--a nationwide population-based study in children and adults. Hamer HM, Dodel R, Strzelczyk A, Balzer-Geldsetzer M, Reese JP, Schöffski O, Graf W, Schwab S, Knake S, Oertel WH, Rosenow F, Kostev K. J Neurol. 2012 Nov;259(11):2376-84.

Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease. Reese JP, Dams J, Winter Y, Balzer-Geldsetzer M, Oertel WH, Dodel R. Expert Opin Pharmacother. 2012 May;13(7):939-58.

Differentially expressed gene profile in the 6-hydroxy-dopamine-induced cell culture model of Parkinson's disease. Noelker C, Schwake M, Balzer-Geldsetzer M, Bacher M, Popp J, Schlegel J, Eggert K, Oertel WH, Klockgether T, Dodel RC. Neurosci Lett. 2012 Jan 17;507(1):10-5

[Health-economic burden of Parkinson's disease in Portugal: a cohort study]. Reese JP, Winter Y, Rosa MM, Rodrigues E Silva AM, von Campenhausen S, Freire R, Mateus C, Balzer-Geldsetzer M, Botzel K, Oertel WH, Dodel R, Sampaio C. Rev Neurol. 2011 Mar 1;52(5):264-74. Spanish.

Costs of illness and care in Parkinson's disease: an evaluation in six countries. von Campenhausen S, Winter Y, Rodrigues e Silva A, Sampaio C, Ruzicka E, Barone P, Poewe W, Guekht A, Mateus C, Pfeiffer KP, Berger K, Skoupa J, Bötzel K, Geiger-Gritsch S, Siebert U, Balzer-Geldsetzer M, Oertel WH, Dodel R, Reese JP. Eur Neuropsychopharmacol. 2011 Feb;21(2):180-91.

Economic burden in a German cohort of patients with multiple sclerosis. Reese JP, John A, Wienemann G, Wellek A, Sommer N, Tackenberg B, Balzer-Geldsetzer M, Dodel R. Eur Neurol. 2011;66(6):311-21.

Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings. Reese JP1, Hessmann P, Seeberg G, Henkel D, Hirzmann P, Rieke J, Baum E, Dannhoff F, Müller MJ, Jessen F, Geldsetzer MB, Dodel R. J Alzheimers Dis. 2011;27(4):723-36.

[Parkinson's disease: cost-of-illness in an outpatient cohort]. Reese JP, Winter Y, Balzer-Geldsetzer M, Bötzel K, Eggert K, Oertel WH, Dodel R, Campenhausen Sv. Gesundheitswesen. 2011 Jan;73(1):22-9.

Parkinson's disease and dementia: a longitudinal study (DEMPARK). Balzer-Geldsetzer M, Costa AS, Kronenbürger M, Schulz JB, Röske S, Spottke A, Wüllner U, Klockgether T, Storch A, Schneider C, Riedel O, Wittchen HU, Seifried C, Hilker R, Schmidt N, Witt K, Deuschl G, Mollenhauer B, Trenkwalder C, Liepelt-Scarfone I, Gräber-Sultan S, Berg D, Gasser T, Kalbe E, Bodden M, Oertel WH, Dodel R. Neuroepidemiology. 2011;37(3-4):168-76.

2. Übersichtsarbeiten

Pharmacoeconomic Considerations of Treating Patients with Advanced Parkinson’s Disease – A Systematic Literature Review-Reese JP, Dams J, Winter Y, Balzer-Geldsetzer M, Oertel WH, Dodel R. (Expert Opinion On Pharmacotherapy 2012; 13(7): 939-958.

Who was the man who discovered the "Lewy bodies"? Rodrigues e Silva AM, Geldsetzer F, Holdorff B, Kielhorn FW, Balzer-Geldsetzer M, Oertel WH, Hurtig H, Dodel R. Mov Disord. 2010;25(12):1765-73.

3. Buchkapitel

Versorgungssituation von Patienten mit neurologischen Erkrankungen in Deutschland. Monika Balzer-Geldsetzer, Richard Dodel, Arne Hillienhof, Uwe Meier. In: Innovative Konzepte im Versorgungsmanagement von ZNS-Patienten MWV Medizinisch Wissenschaftliche Verlagsgesellschaft Berlin 2010